Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

1326 ARTÍCULOS , VIENDO DEL 496 AL 510

Cell death targets and potential modulators in Alzheimer's disease

Castro RE, Santos MM, Glória PM, Ribeiro CJ, Ferreira DM, Xavier JM, Moreira R, Rodrigues CM.

Curr Pharm Des. 2010;16(25):2851-64. doi: 10.2174/138161210793176563.

Nitric oxide: target for therapeutic strategies in Alzheimer's disease

Fernandez AP, Pozo-Rodrigalvarez A, Serrano J, Martinez-Murillo R.

Curr Pharm Des. 2010;16(25):2837-50. doi: 10.2174/138161210793176590.

Neuroinflammation, oxidative stress and the pathogenesis of Alzheimer's disease

Agostinho P, Cunha RA, Oliveira C.

Curr Pharm Des. 2010;16(25):2766-78. doi: 10.2174/138161210793176572.

Neurotoxicity of β-amyloid protein: oligomerization, channel formation, and calcium dyshomeostasis

Kawahara M.

Curr Pharm Des. 2010;16(25):2779-89. doi: 10.2174/138161210793176545.

Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease

Medina M, Avila J.

Curr Pharm Des. 2010;16(25):2790-8. doi: 10.2174/138161210793176581.

Structural determinants of the multifunctional profile of dual binding site acetylcholinesterase inhibitors as anti-Alzheimer agents

Galdeano C, Viayna E, Arroyo P, Bidon-Chanal A, Blas JR, Muñoz-Torrero D, Luque FJ.

Curr Pharm Des. 2010;16(25):2818-36. doi: 10.2174/138161210793176536.

Review: omega-3 and memory function: to eat or not to eat

Itua I, Naderali EK.

Am J Alzheimers Dis Other Demen. 2010 Sep;25(6):479-82. doi: 10.1177/1533317510376943. Epub 2010 Aug 11.

Inaccuracy in clinical trials: effects and methods to control inaccuracy

Kobak KA.

Curr Alzheimer Res. 2010 Nov;7(7):637-41. doi: 10.2174/156720510793499057.

Blood-brain-barrier models for the investigation of transporter- and receptor-mediated amyloid-β clearance in Alzheimer's disease

Pflanzner T, Kuhlmann CR, Pietrzik CU.

Curr Alzheimer Res. 2010 Nov;7(7):578-90. doi: 10.2174/156720510793499066.

Why so few drugs for Alzheimer's disease? Are methods failing drugs?

Becker RE, Greig NH.

Curr Alzheimer Res. 2010 Nov;7(7):642-51. doi: 10.2174/156720510793499075.

Discrimination of normal aging, MCI and AD with multimodal imaging measures on the medial temporal lobe

Jhoo JH, Lee DY, Choo IH, Seo EH, Oh JS, Lee JS, Lee DS, Kim SG, Youn JC, Kim KW, Woo JI.

Psychiatry Res. 2010 Sep 30;183(3):237-43. doi: 10.1016/j.pscychresns.2010.03.006. Epub 2010 Aug 11.

Cognitive stimulation therapy in the treatment of neuropsychiatric symptoms in Alzheimer's disease: a randomized controlled trial

Niu YX, Tan JP, Guan JQ, Zhang ZQ, Wang LN.

Clin Rehabil. 2010 Dec;24(12):1102-11. doi: 10.1177/0269215510376004. Epub 2010 Aug 16.

Epigenetic regulation of the INK4b-ARF-INK4a locus: in sickness and in health

Popov N, Gil J.

Epigenetics. 2010 Nov-Dec;5(8):685-90. doi: 10.4161/epi.5.8.12996. Epub 2010 Nov 1.

Does executive impairment define a frontal variant of Alzheimer's disease?

Woodward M, Brodaty H, Boundy K, Ames D, Blanch G, Balshaw R; PRIME Study Group.

Int Psychogeriatr. 2010 Dec;22(8):1280-90. doi: 10.1017/S1041610210001596. Epub 2010 Aug 19.

The role of tumor necrosis factor-alpha in cognitive improvement after peroxisome proliferator-activator receptor gamma agonist pioglitazone treatment in Alzheimer's disease

Hanyu H, Sato T, Sakurai H, Iwamoto T.

J Am Geriatr Soc. 2010 May;58(5):1000-1. doi: 10.1111/j.1532-5415.2010.02841.x.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias